Swiss National Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Swiss National Bank’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$758K	Sell	94,600 -12,600	-12%	-$108K	﹤0.01%	2256
2026 Q1	$861K	Hold	107,200	–	–	﹤0.01%	2196
2025 Q4	$1.25M	Buy	107,200 +22,900	+27%	+$223K	﹤0.01%	2077
2025 Q3	$847K	Hold	84,300	–	–	﹤0.01%	2217
2025 Q2	$1.47M	Buy	84,300 +8,600	+11%	+$124K	﹤0.01%	1959
2025 Q1	$952K	Hold	75,700	–	–	﹤0.01%	2149
2024 Q4	$799K	Hold	75,700	–	–	﹤0.01%	2296
2024 Q3	$1.1M	Buy	75,700 +9,700	+15%	+$115K	﹤0.01%	2174
2024 Q2	$562K	Hold	66,000	–	–	﹤0.01%	2394
2024 Q1	$675K	Hold	66,000	–	–	﹤0.01%	2389
2023 Q4	$362K	Sell	66,000 -16,300	-20%	-$71.4K	﹤0.01%	2511
2023 Q3	$311K	Hold	82,300	–	–	﹤0.01%	2581
2023 Q2	$551K	Buy	+82,300	New	+$549K	﹤0.01%	2518
2021 Q4	–	Sell	-23,100	Closed	-$231K	–	2747
2021 Q3	$231K	Hold	23,100	–	–	﹤0.01%	2618
2021 Q2	$714K	Buy	+23,100	New	+$741K	﹤0.01%	2574

Other funds holding SPRY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

PCML

Pavaki Capital Management LLC Pueblo, Colorado $287M AUM

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

Swiss National Bank's SPRY Position: Q2 2026 in Review

Swiss National Bank reduced its ARS Pharmaceuticals (SPRY) stake by 12% in Q2 2026, selling an estimated $108K and leaving 94,600 shares worth $758K. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Swiss National Bank first reported a position in SPRY in Q2 2021 and has held it in 15 quarters since. The position peaked at $1.47M in Q2 2025. 85 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Swiss National Bank held 94,600 shares of ARS Pharmaceuticals worth $758K as of Q2 2026.
Swiss National Bank sold 12,600 ARS Pharmaceuticals shares in Q2 2026, an estimated $108K.
ARS Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2256 holding.
Swiss National Bank first reported a position in ARS Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
Swiss National Bank's ARS Pharmaceuticals position peaked at $1.47M in Q2 2025.
85 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.